Daré Bioscience, Inc. (NASDAQ:DARE) Q3 2023 Earnings Call Transcript

Daré Bioscience, Inc. (NASDAQ:DARE) Q3 2023 Earnings Call Transcript November 9, 2023

Daré Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.1.

Operator: Welcome to the conference hosted by Daré Bioscience to Review the Company’s Third Quarter Financial Results and to provide a General Business Update. This call is being recorded. My name is Chris and I will be your operator for today. With us today from Daré are Sabrina Martucci Johnson, President and Chief Executive Officer; John Fair, Chief Commercial Officer; and Lisa Walters-Hoffert, Chief Financial Officer. Ms. Johnson, please proceed.

Sabrina Martucci Johnson: Thank you. Good afternoon, and welcome to the Daré Bioscience financial results and business update call for the quarter ended September 30, 2023. Today we will review our third quarter results, and discuss developments and expectations for our pipeline and portfolio. Before we begin, I would like to remind you that today’s discussion will include forward-looking statements within the meaning of federal securities laws which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts, should be considered forward-looking statements. Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties.

You should not place undue reliance on forward-looking statements. Forward-looking statements are qualified in their entirety by the cautionary statements in the company’s SEC filings, including our Form 10-Q for the quarter ended June 30, 2023 which was filed today. I would also like to point out that the content of this call includes time-sensitive information that is current only as of today, November 9, 2023. Daré undertakes no obligation to update any forward-looking statements to reflect new information or developments after this call, except as required by law. For those of you joining us via webcast, you should be able to access presentation slides from within the webcast module. We’ve included these slides to provide some additional context to our portfolio that you may find helpful while you listen to the call.

The slide deck is also available on the Investor Relations section of our website under Presentations, Events and Webcasts, and will remain on the site for two weeks. As you know, our sole focus at Daré is women’s health. Women’s health products make up 27% of total blockbuster products while contributing to 35% of total blockbuster sales, and there continue to be many unmet needs in the market. We believe we have an exceptionally strong pipeline of product candidates that positions us well for the short, medium and long-term. I’m excited to share today the recent strides we’ve made to advance innovative therapies for women with our most promising near-term opportunities. Since the beginning of the third quarter, we have had several important achievements.

First, we achieved our first commercial milestone for XACIATO, which was the initial shipment of the product associated with the launch. Second, we shared additional positive data from our Phase 2b RESPONSE study of Sildenafil Cream, which has the potential to be the first FDA-approved treatment for any form of sexual arousal disorder in women. And third, we made further progress toward patient enrollment for the anticipated start of our pivotal Phase 3 study of Ovaprene, our potentially first-in-class hormone-free monthly intravaginal contraceptive candidates. Overall, we continue to advance our key pipeline programs, each of which, if approved, represents a potential first line or first-in-category opportunity. Additionally, we are actively engaging our commercialization collaborators, including leading players in women’s health, Organon and Bayer as we steadily execute on our mission to accelerate innovative treatments that women want and need.

I’ll now provide an update on our potentially disruptive late-stage candidates, Sildenafil Cream and Ovaprene. Then John will provide an update on XACIATO’s launch, and Lisa will review our financial results for the quarter ended September 30. So let’s start with Sildenafil Cream, which is our investigational therapeutic candidate to treat female sexual arousal disorder, or FSAD, and female sexual interest arousal disorder or FSIAD. Last week, we announced additional updates from our Phase 2b RESPONSE study results in preparation for our confirmed upcoming and the Phase 2 FDA meeting this year. Sildenafil, which is a PDE5 inhibitor, is the active ingredient in a tablet for oral administration currently marketed under the brand name Viagra for the treatment of ED erectile dysfunction in men, which was undoubtedly one of the most successful prescription products ever launched.

Our Sildenafil cream is an investigational proprietary topical treatment, cream formulation, specifically designed to be used on demand at the time of sexual activity to increase blood flow to the genital tissue in women. If development is successful, Sildenafil Cream has the potential to be the first FDA-approved product to treat any form of arousal disorder in women. Women who experienced no or low sexual arousal are bothered by and dissatisfied with their sex lives. They’re frustrated with their sexual problems. They experienced guilt about their sexual difficulties and they are likely to feel sexually inadequate, inferior and embarrassed. Market research suggests that approximately 20 million women in the U.S. aged 21 to 60 experience symptoms of low or no sexual arousal, and approximately 10 million women are considered distressed and actively seeking treatment.

We believe this is a promising untapped market given the numerous equivalent products approved for men, not only Viagra, but also Cialis and Levitra, to name a few. Last week, we announced additional positive data from our Phase 2b RESPONSE study of Sildenafil Cream, having completed our study analysis in preparation for our upcoming FDA meeting. Importantly, these additional analyses indicate that we can use our Phase 2b study approach in Phase 3. Specifically, this means we can propose a Phase 3 study with the same co-primary endpoint structure that we used in Phase 2b, which assesses arousal sensation and evaluates concerns related to the difficulties of the sexual arousal. And two, that we can propose that in the Phase 3 study, we evaluate Sildenafil Cream in a broader patient population of women that, includes not only women with arousal disorder only or FSAD, but also those with arousal plus desire disorder, otherwise stated as women with female sexual interest arousal disorder or FSIAD.

This would be the first ever Phase 3 pivotal study of a therapeutic candidate for the treatment of arousal disorder in women, and we remain on track for in the Phase 2 meeting with the FDA this year. We look forward to keeping you updated on those developments. Now I’d like to turn to Ovaprene. Ovaprene is our investigational, potentially first-in-category hormone-free, monthly intravaginal contraceptive. We have been working closely with our Phase 3 study collaborator, the National Institute of Child Health and Human Development or NICHD of the NIH on the pivotal study planned to start later this year. The pivotal Phase 3 study of Ovaprene is being supported by NICHD’s contraceptive development program, which oversees the contraceptive Clinical Trials Network or CCTN, which was established in 1996 to conduct studies of investigational contraceptives like Ovaprene.

We remain on track to start enrolling patients this fourth quarter of 2023, and we will issue an announcement after the first patient is enrolled. As a reminder, the study is a multicenter, single-arm non-comparative pivotal Phase III contraceptive study of Ovaprene to evaluate its effectiveness as a contraceptive along with its safety and usability. Based on our communications to-date with the FDA, if successful, we believe that only this single registration study will be required to support a premarket approval application submission with the FDA. We believe Ovaprene has the potential to be a disruptive product in the contraceptive category and potentially life-changing for women who cannot take hormone-based therapies such as some cancer patients or those who would prefer not to do so.

In fact, survey data indicates that nearly 85% of women would prefer a monthly option with a lower hormone dose than the oral birth control pill. In addition to providing innovation as a non-hormonal contraceptive, the clear differentiation and disruptive potential of Ovaprene is in its convenience and potential efficacy. Its convenience includes easily monthly use and self-administration without requiring action at the time of intercourse with target efficacy approaching hormonal birth control methods. There are currently no FDA-approved monthly hormone-free contraceptive. And based on market research, approximately 35 million women in the U.S. are potential candidates for Ovaprene. We see parallels to NuvaRing when it entered the market as the first monthly intravaginal hormonal contraceptive and to Mirena, when it entered the market as the first hormone-releasing intrauterine system, and Bayer, which commercializes Mirena is a leader in commercializing contraceptive products in the United States, and they hold the U.S. commercial rights to Ovaprene under a license agreement with us.

In summary, I am very excited about the progress we’ve made on our late-stage program since our last call in August. As the only company solely focused on developing women’s health products, Daré is developing first-in-category products. Our investigational products are some of the most potentially disruptive candidates for women in decades. And we collaborate with leading companies to commercialize and deliver these treatments to as many women as possible. And as you’ll hear from Lisa later on this call, we do all of this with thoughtful and efficient capital deployment and leveraging non-dilutive sources of capital wherever feasible. I’ll now turn it over to John to provide a commercial update on the Organon/XACIATO launch as well as Ovaprene pre-commercialization activities underway in collaboration with Bayer.

John Fair: Thank you, Sabrina. As a reminder, XACIATO, clindamycin phosphate vaginal gel is limcosamide antibiotic for single-dose vaginal administration indicated for the treatment of bacterial vaginosis or BV in female patients 12 years of age and older in the United States. As many of you know, Organon recently launched XACIATO. The product is in the channel as of last month, and the initial focus in Q4 is on high BV prescribers in the U.S., aligned to end-of-year product availability in select retail pharmacies. As we have communicated on previous calls, Organon’s go-to-market strategy leverages the knowledge and experience of the established NEXPLANON commercial team. Organon believes there’s a roughly 95% overlap of healthcare providers who prescribe their contraceptive product NEXPLANON that also have the potential to prescribe XACIATO based on provider treatment patterns.

And to drive product pull-through, their skilled market access team is meeting with customers to review XACIATO. Because of the strong relationships the Organon sales team has with these healthcare providers, we expect them to be well positioned to detail XACIATO. Looking ahead to our Phase 3 trial initiation for Ovaprene, we are excited to begin Phase 3 study activities with our U.S. commercial collaborator, Bayer. In parallel, our team has been collaborating with Bayer on key downstream commercial initiatives intended to ensure a seamless transition from clinical development to commercial introduction. These activities will help set the foundation to maximize the value of this disruptive technology. With that, I’ll turn the call over to Lisa.

Lisa Walters-Hoffert: Thank you, John, and thanks, everyone, for joining us today. I would now like to summarize Daré’s financial results for the third quarter of 2023. For those of you who are newer to the story, Daré’s business strategy is to assemble in advance a portfolio of differentiated product candidates that address meaningful unmet needs that we’ve identified in women’s health, and then to monetize the value of our portfolio’s clinical and regulatory advances over the near and long-term. The investment required to build and advance a portfolio includes corporate overhead, portfolio acquisition and maintenance costs and of course, ongoing research and development or R&D expenses. So during the third quarter of 2023, our general and administrative or G&A expenses were approximately $2.7 million, unchanged from G&A expenses recognized during the third quarter of 2022.

Our R&D expenses, which vary from period-to-period based on clinical, preclinical, manufacturing, regulatory and other activities across our entire portfolio, were approximately $6.7 million and primarily reflect the costs related to the Sildenafil Cream Phase 2b clinical trial and manufacturing and regulatory affairs activities related to Ovaprene’s planned Phase 3 study. While my comments have focused largely on our expenses, I should note that during the third quarter, we also recognized license fee revenue of $1 million under our global license agreement with Organon. Our comprehensive loss for the third quarter was approximately $8.3 million. We ended the third quarter with approximately $13.9 million in cash and cash equivalents and as of November 8, we had approximately 98.6 million shares of common stock outstanding.

So moving to the fourth quarter of 2023. Under our license agreement with Organon, we will receive a $1.8 million commercial milestone payment as a result of the first shipment of XACIATO in connection with its launch in the U.S. during the quarter. Thereafter, we will receive tiered double-digit royalties based on net sales as well as additional potential milestones of up to $180 million over time. Now that the sales efforts have commenced by Organon, Daré will begin to recognize estimated revenues in our financial statements, reflecting the royalties from XACIATO’s net sales. It goes without saying that we at Daré are thrilled that XACIATO is now available in the U.S., and I look forward to reporting on XACIATO’s progress in the months ahead for all Daré stakeholders.

I started my remarks with a review of our business strategy, so it now feels appropriate to take a moment and review our financial strategy. Since our inception, we have made fiscal responsibility a top priority, maintaining a lean and focused team and managing our overhead costs closely. In the current challenging market, we have reduced costs and are exploring additional opportunities to reduce costs when appropriate and where appropriate, but seeking to do so without compromising our focus on investing and cultivating our leading product candidates. We are looking at a wide range of opportunities to fund our high-quality portfolio, including more creative and innovative vehicles that other companies may not have access to. Based on conversations to-date, we’ve been believed by the depth and advancement of our portfolio and our pipeline, and we are actively pursuing options to raise capital.

As we’ve said previously and as Sabrina just noted, we will endeavor to be creative, collaborative and opportunistic in seeking the capital needed to meet our objectives and to build shareholder value. Again, as a reminder, these include, but are not limited to, non-dilutive grants, similar to those that we have obtained to finance many of our preclinical programs, equity sales, license agreements, structured financings and strategic collaborations and alliances. We have explored and will continue to explore a variety of options to fund our operations, advance our candidates, monetize the value of our assets and build shareholder value. We encourage investors to read the more detailed discussion of our financials, financial condition, liquidity, capital resources and Risk Factors in our Form 10-Q for the quarter ended September 3, 2023, which was filed today as well as in our annual report on Form 10-Q for the year ended December 31, 2022, which was filed on March 30, 2023.

I would now like to turn the call over to the operator for Q&A.

Operator: Thank you. [Operator Instructions] The first question is from Catherine Novack with Jones Trading. Your line is open.

Catherine Novack: Hi. Good afternoon. Thanks for taking my questions. A couple on Ovaprene. First is, do you plan to issue periodic updates regarding enrollment? And is it possible that we might expect to see updates on some of the efficacy endpoints potentially before the top line data readout?

See also 14 Best Beauty Stocks To Buy Now and Best Dog Foods for Puppies and Small Dogs.

Q&A Session

Sabrina Martucci Johnson: Hi. Thank you for the great questions, and thanks for asking about Ovaprene. Obviously very excited that the study is starting. In terms of providing updates, that definitely is our intention. As we’ve – as a reminder to people, the study duration is 13 cycles, which is about 12 months. So that’s how long the women in the study will be using Ovaprene over the course of that period. And as we’ve guided in terms of how long the study will take beyond that, it really comes down to the enrollment rate. So, we do really want to keep people informed as the study progresses. So that’s definitely our intent. The first announcement you’ll get is that first patient enrolled and then we do intend to keep people updated as enrollment progresses as we have information that is suitable for that.

And in terms of providing data updates, that’s really a fantastic question as well, because as you probably noted in the comments, it is a non-comparative study, which means everyone is on Ovaprene, everyone gets Ovaprene in the study. And in contraceptive studies, you’re looking at pregnancy rates over time. Having said that, right now, there’s not necessarily a plan to disseminate any data before the study is completed. However, that is something that certainly we are discussing with our collaborators at the NICHD who are collaborating with us on the study in terms of the merits of doing that and whether not there might be a situation where that makes sense. So, we will keep you posted on that as well.

Catherine Novack: Great. And can you remind me – us the estimated cost of this Ovaprene study and to what extent it’s already funded in some part by NICHD?

Sabrina Martucci Johnson: Yes. So just as a reminder for everyone, and thank you for asking the question, so that we can do that. Because it’s kind of a nice position to be in to have a Phase 3 study starting that actually we already paid for. And so the way the collaborative research agreement works with the NICHD is we have already provided into an account basically under that [indiscernible] $5 million towards the cost of the study. And then obviously, the NICHD is providing resources as well to cover the cost of the study. And right now, we’re working through the contraceptive clinical trial network, which is the 20 sites that the NICHD works with on these types of studies. And so that – those costs and our funding to the NIH was really based on our determination with them and our CRO partner that they work with on these studies in terms of the anticipated costs and needs of the programs.

Obviously, there’s always a potential for us to provide additional funding under circumstances, for instance, if we felt we wanted to add sites or things like that. But right now, the study is funded for what is planned currently. It’s obviously underway. And based on the funding that’s been provided, and also just the way the NICHD does their contracts, that really even. And we actually touched on this in our 10-Q related to questions we might get about what happens if there’s a government shutdown, even just the way they do their contracts, it kind of obligates the funds out so – through the third quarter of next year. So that’s the plan right now with the study.

Catherine Novack: Okay. That’s helpful. And then if I can just get in one more on the Sildenafil Cream. So you’re moving this product into pivotal studies, are you considering partnerships as you did with Ovaprene, XACIATO either regional or U.S. based? And at what point do you think it makes sense to start having those partnering discussions?

Sabrina Martucci Johnson: Yes. So as we noted upfront, we’re very proud that we are in collaboration with some of the leaders in women’s health, including Organon and Bayer. And as you’ve noted, we’ve entered into those partnerships in different times through different programs. So with Ovaprene, as you noted, we entered into that collaboration before the Phase 3 trial. Whereas with Organon and XACIATO, we entered into that collaboration after that product was taken all the way through registration. Every product is different. Obviously, as – I hope it’s obvious given everything we talked about today. Sildenafil Cream is a very interesting program. There is nothing approved for female sexual arousal disorder. And so given that, it’s an interesting program.